Projects and Grants
MS-SCI-MS offers persons with new or with longstanding SCI opportunities to participate in clinical trials of new drugs and other interventions that may decrease the impairment, or increase one's ability to function independently. In the last two decades, MS-SCI-MS has participated in most trials of new SCI drugs, including Sygen (GM 1), 4-Aminopyridine (4-AP) and HP184. In addition, Mount Sinai staff and faculty conduct research on many other aspects of SCI treatments and outcomes, collaborating with the most prominent researchers in the USA and elsewhere. Some of the research is funded by the National Institute on Disability and Rehabilitation Research; sponsors of other projects include pharmaceutical industry and non-profit organizations.